Zydus and MSN Launch First Generic of Adempas in the US
Zydus Lifesciences Ltd 路 Press Release 路 06 Oct 2026, 2:14 am
Zydus and MSN Launch First Generic of Adempas in the US Zydus Lifesciences partnered with MSN Laboratories to launch the first generic version of Adempas (Riociguat Tablets) in the US across all five strengths (0.5 mg to 2.5 mg) following USFDA approval. Developed and manufactured by MSN, the drug treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The first-to-market generic launch captures significant commercial potential, targeting a therapy where branded Adempas recorded global sales of ~EUR 745mn (~$850mn) in CY25, strengthening Zydus's specialty complex-generics US portfolio.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
